Member Info for The_Paladin

Titania. As always, thank you for sharing your shrewd detective work with this forum. Should the job advertisement be Synairgen-related, I wonder why haven's they displayed it in the 'current available positions' section on Synairgen's website?

Thank you for checking that out Mani. That was a strange answer from Brooke Clarke. You expressed a legitimate interest as an investor as to whether one or both of these positions had been filled? Surely a direct answer would not be deemed as market sensitive information? Looking at the VP appointments during the last two years, the only one that I could find declared in an RNS was that of Dr Gareth Walters as CRO on Oct 13, 2021. I cannot remember how the other recent senior management posts were announced, but assume that I read about them in contributions from an eagle eyed investor on this forum? As the recent posts were not at a similar level, perhaps the company does not deem it appropriate to confirm the appointments? Provided, of course, both of these posts were filled?

I totally agree that the only important current announcement is whether Richard Marsden and his senior leaders have been successful in negotiating a P3 trial for SNG001 - either a PT or a trial in partnership with a BP company? Nothing else matters for the time being. Very promising results have been collated in recent months, and have been variously presented at major conferences, which leads to some optimism.

We have no idea of any progress made, or otherwise? Consequently I choose to reject any negativity concerning this issue on a small discussion forum. There is very little trading of Synairgen shares at the moment, IMHO mostly the actions of speculative short-term traders? Some attempt to spread negativity on this forum, but to little effect. Most of it has no foundation. I believe that most LTIs are following TFG Asset Management's lead, and holding their shares pending a significant development? The RNS information that investors have received in the last six months is positive. It has had zero net effect on the share price. This is because it does not lead to any income generation, although it has signalled the potential of SNG001 to do so. The ball is very much in Synairgen's court; as investors we can but wait to receive updates from the company.

GLA

Trolls like Professional and viletrader (both green binned on my screen but I noticed that both were mentioned earlier) seem to emerge at quiet periods when there is little trading? Synairgen has probably provided traders like these with occasional profits in recent months? It is probably best to follow aether’s oft repeated advice and obliterate their self- serving messages.

Unfortunately, this forum is attracting unwanted pessimism and cynicism from traders at the current time. Richard Marsden needs to unleash the dogs as soon as he is able. This will put an end to comments like these for good.

I wasn’t invested at the time, but did the board attract similar comments before the P2 trial results in July 2020? Any uncertainty attracts traders who benefit from the hasty actions of insecure investors.

I have been invested for well over two years. Sadly, I didn’t sell any shares when I should have, but intend to remain fully invested to see whether my “gamble” pays off? Following the updates in recent months, we have a fighting chance of success. Richard Marsden and the Synairgen team will need to be at their level best to ensure that the right result is achieved both for the company and its LTIs.

GLA.

GLA.

Great research cmww2014.

Dr Mark Main, whose (main) company is Pulmonarius Ltd, appears to be an independent consultant. His company was first listed in March 2018, has two employees, Dr Main, and his wife, and appears to be based at their home address.

https://find-and-update.company-information.service.gov.uk/company/11236620/officers

“Pulmonarius provides consultancy and development support to companies engaged in respiratory drug and device development, and conducts diligence research on novel products and therapeutic uses in respiratory medicine.”

Dr. Main is 63 next month, which tallies with the photograph. I failed to find another photograph anywhere.

He is also listed as a director of a small West Sussex company, Thromboserin Ltd.
https://find-and-update.company-information.service.gov.uk/company/06254958/officers

The question remains whether he attended the ID2022 conference as a consultant to the Synairgen team? Surely not? What expertise was needed in addition to that copiously met by the four senior Synairgen employees in the photograph? Three of the employees have been involved in the business for well over a decade. Richard Marsden gives science-based presentations very competently. Dr. Monk has the most detailed grasp of all aspects of the treatment process. Richard Hennings, our CCO, lists the following as part of his LinkedIn profile.
* Experience across therapeutic areas including: respiratory, orphan disease, anti-infectives, anti-virals & oncology.
* Passionate about realising the full potential of innovative therapies that significantly impact patients who are facing adversity.

Perhaps we will never know, but if it proves to be the case, why would Synairgen need the services of an additional consultant ? Its team already had at least four employees attending, with a very high level of the required knowledge and expertise to induce interest in SNG001 ?

Mr. Costs.

I am growing bored with your pointless negativity on this forum. Anyone who thinks that this investment isn’t going to recover should presumably follow their judgement by selling their holding, and investing elsewhere?

It’s your business what you choose to do , but having taken the decision to stay with your investment, perhaps the time has come for you to stop moaning on here.

Why not let it all out by writing a letter to the company, or specifically to Richard Marsden, as our CEO? It is more his role to deal with investors’ disaffection than that of other investors on this board, who are trying to remain positive following some promising trial outcomes this year. Good luck to you, but do stop moaning about a situation that you, or any other investor, cannot change.

Onwards and upwards. One piece of news about an alliance with a BP company could instantly change the current situation. This is my current hope, and I shall continue to monitor the RNS situation on a daily basis to see what develops?

GLA.

Please keep contributing Docdaneeka and Ghia. This forum would be dull and lifeless if everyone held the same opinions. I am appreciative of the opinions of all LTIs here, even those who are cynical about my contributions. The occasional “visitors”, who have their own agendas, are best filtered or ignored.

Those Quatari stadia have really taken shape Doc. It would be a shame to tear them down after the tournament.
https://www.stadiumguide.com/tournaments/fifa-world-cup-2022-stadiums-qatar/

This forum is attracting occasional visitors, with their own particular theories and agendas, this evening.

As we discovered last February, an investment can yield disappointing results in complete contrast to the expectations of the vast majority of LTIs, who had invested time for extensive research, and considerable capital sums in this company. Despite this, the research has continued relentlessly since then. The belief in the future potential of SNG001 remains.

Why should we take on board the opinions of individuals who have little commitment to, or interest in, Synairgen? They evidently comment on bulletin boards for their own particular advantage, whatever that may be? Their tone is invariably carefully chosen so as to attempt to unnerve investors.

Most long term investors will continue to follow their own opinions based on research, and their beliefs in what the future holds. Others are welcome to their opinions, and are free to state them here. Time will tell whose reasoning is correct as regards Synairgen’s future?

GL to all LTIs.

Recently, this forum has become rife with silly speculation. Why does Synairgen desperately need to be accepted on a trial in the next seven weeks? Why would a high-level investment company like TFG Asset Management want to acquire a small bio-pharmaceutical company and trial and market a treatment themselves subsequently? Why would investors contemplate surrendering their shares at a fraction of the amount that they cost them?

The facts are simple. Synairgen have recovered well from a very unfortunate event over eight months ago. It has brought the analyses of results and data from various trials up to date, and has received the top line analysis from a trial conducted by the NIH. All these analyses demonstrate the potential of SNG001 as a broad spectrum antiviral treatment; in addition some benefit has been discovered in averting long term symptoms when treating patients with Covid-19. The company are currently seeking to move forward and discussions are underway to establish the optimal route to further trialing and subsequent commercialisation.

IMHO, it is better for one’s wellbeing to try and maintain a positive outlook, rather than whinge about the current situation and the company’s history, or explore the worst case scenarios that might develop.

We are where we are. There doesn’t seem to be a great deal going on at present, but who knows what is happening behind the scenes? Positive news could emerge at any time which could change investors’ outlook and aspirations.

GLA.

Dr. Monk is one of 140 speakers presenting at this conference. It is essential for the company to attend events of this stature in order to present their case for investment/partnership to relevant parties.

It is very difficult to make a case in the current low Covid (relatively speaking) backg. Synairgen receive very little attention on LinkedIn or twitter. They are doing their level best, but will need to continue to keep going full throttle to secure that elusive trial. When this is achieved, and there is a viable route towards commercialisation, our current situation should improve.

GLA.

https://www.terrapinn.com/conference/world-antiviral-congress/index.stm

Much of our recent discussion has been focused on competing therapies (with SNG001) for trials. I am interested in the nature of any available trial in principle, and how they would apply to SNG001?

1. The trial protocols?
2. The time scale?
3. The cost to Synairgen, and their degree of involvement in the trial?
4. What effect would a firm acceptance on a suitable trial have on the share price?
5. What would the share price be at the successful conclusion of a trial?
6. What role TFG Asset Management might play?
7. Would trial inclusion induce any interest from a BP company ?
8. These questions are simplistic, and a trial’s circumstances would change according to its nature (Joint Venture or Platform Trial?).
9. Bearing in mind the conduct of previous trials, the trial design, and the conditions under which it is executed are very important. SNG001 must be given the best opportunity to succeed next time around.

Before this conversation or any recent conversation becomes relevant, Synairgen must first secure a place on a trial. Otherwise another fund raise to finance a trial, with associated share price dilution may be necessary. To end on a positive note, there has been an aggregate of positive trial data and results recently, and the latter has been presented well to significant audiences at international conferences.

From their recent statements, Synairgen are hopeful of a successful outcome to the latter.

“We aren’t disclosing the specifics of our discussions and applications with specific trials but as soon as we have a concrete trial or trials agreed we will make an announcement.“

GLA.

I have asked the question on Twitter as suggested by Docdaneeka. Perhaps a member of the Synairgen team will enlighten us?

An interesting comment:
“3 million hospitalisations per year due to respiratory viral infections as projected for 2022 and onwards on the US alone”

Why would an UK-based company use an US statistic to promote its message? Is it because of the immense number suffering from viral respiratory infections on the US, or could there be another reason?

I agree with a previous comment that the positive information flow from the company has increased recently, as was the case on early January. Here’s hoping that whatever follows will result in a good outcome for long term investors this time around,

Monday morning has arrived, and we still haven’t identified Dr Mark, who is posed centrally in the ID2022 team photo with the Synairgen four ?

Wigster77/Bannos8888

The lady in the team photo with our three gentlemen wasn’t Maud, but Vicki Tear, Synairgen’s VP (Non clinical operations). Note that the four Synairgen employees have corporate coordination with their ‘Synairgen blue’ shirts.
https://uk.linkedin.com/in/vicki-tear-35aa58159

I still haven’t worked out who Dr. Mark is? My wish is that he turns out to be from a BP company, with an interest in working with us. :-)

ATB.

In the team photograph, together with the three gentlemen in their matching ‘Synairgen blue’ shirts, I believe that the lady on the right is Vicki Tear (Synairgen’s VP Non-clinical Operations). She shares the same corporate look as the three gentlemen.
https://uk.linkedin.com/in/vicki-tear-35aa58159

I haven’t been able to work out who Dr. Marc …. At centre stage is. He is not, presumably, a Synairgen employee, but may be an advisor/consultant working with our team?

Hasn’t this (CTAP) programme been up and running since early 2020?

https://www.seyfarth.com/news-insights/fda-announces-the-creation-of-ctapcoronavirus-treatment-acceleration-programto-assist-drug-developers-and-evaluators.html

A clear and concise presentation of the Sprinter trial methodology and outcomes with a focus on Long Covid. It will have given the BP attendees something to think about.

It was good to see that the company was well represented at the conference. I agree that there is a good possibility that this, together with all the positive updates from Synairgen this year, could well lead to a JV with a BP partner as Winter approaches.

GLA.

J_CIT

The opinion that I think you are offering isn’t at all clear? I am not sure what your point is? Have you kept in touch with the developments that Synairgen have announced in recent months? If so you would not be making unjustified comments like “dead in the water”?

You sound like one or two others who occasionally frequent this board making similar remarks? You are wasting your time. The majority of contributors here are LTHs, who mostly believe that the company has a very good chance of staging a good recovery from the current share price levels.

The company’s strategy is based on the following statement :
“While prudently managing costs, we are actively pursuing and refining multiple clinical approaches including company- and investigator-sponsored studies and possibly platform studies (as and when appropriate), to confirm the most expeditious clinical development path for SNG001 in patients hospitalised due to a severe viral lung infection including SARS-CoV-2, influenza, RSV, adenovirus, parainfluenza and rhinoviruses.”

They will update investors as quickly as there is something to add to that statement. I would be surprised if we haven’t heard anything before Winter sets in.

GLA.

There has been no reaction yet to Dr. Monk’s presentation at last week’s ID2022 Conference. We can now assume that nothing significant was added to the recently RNSd LC data?

Brooke Clarke’s recent e mail to investors inform us that wheels are turning, and there are several possible ways forward?

“We continue to actively pursue and refine multiple clinical approaches including company and investigator-sponsored studies and possibly platform studies (as and when appropriate), to confirm the most expeditious clinical development path for SNG001 in patients hospitalised due to a severe viral lung infection including SARS-CoV-2, influenza, RSV, adenovirus, parainfluenza and rhinoviruses.

We aren’t disclosing the specifics of our discussions and applications with specific trials but as soon as we have a concrete trial or trials agreed we will make an announcement.”

It seems likely to me that a SNG001 trial will result either from a PT invitation or from JV negotiations. What are the time scales involved to arrive at a trial confirmation? Is the treatment of patients during the coming Winter mentioned by Richard Marsden still viable? If neither of the above options materialise would Synairgen aspire to another investor-funded trial with the issue of more shares and an associated dilution? Does TFG Asset Management have a role to play in any future developme? Would a BP company be interested in adding Synairgen’s broad spectrum antiviral treatment to its product pipeline?

I remain encouraged by the progress made since last February and look forward to an announcement of the next steps that Synairgen will pursue towards achieving the commercialisation of SNG001.

GLA